Zobrazeno 1 - 10
of 6 947
pro vyhledávání: '"ADVANCED BREAST-CANCER"'
Publikováno v:
Acta Medica Bulgarica, Vol 51, Iss 4, Pp 64-68 (2024)
Breast cancer is a pathology associated with high morbidity and mortality among women of all nations worldwide. The low efficiency or total absence of national screening programs, the presence of comorbid mental illnesses or dementia, general lack of
Externí odkaz:
https://doaj.org/article/8cd65615e51345918ad6056f7045edbc
Publikováno v:
Breast Cancer: Targets and Therapy, Vol Volume 16, Pp 761-768 (2024)
Minghui Li,1,* Yuelin Liu,1,* Xu Han,1,* Tao Li,2 Zhizheng Zhang,1 Ningyi Xue,1 Mengdi Liang,1 Ge Ma,1 Tiansong Xia1 1Department of Breast Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, People’s
Externí odkaz:
https://doaj.org/article/6925d341bdbc4c3aa69e679e0c46e5ad
Autor:
Farhad Ghasemi, Muriel Brackstone
Publikováno v:
Current Oncology, Vol 31, Iss 10, Pp 6007-6016 (2024)
The utility of neoadjuvant chemotherapy is expanding in the treatment of breast cancer. Although individual trials have shown comparable survival between patients receiving neoadjuvant and adjuvant chemotherapy, large-scale data analyses for outcomes
Externí odkaz:
https://doaj.org/article/d077cdeeda2e4cb0b324700a150d6263
Autor:
Nathan A. Clarke, Brendon Wong, Rachael Lawrance, Anders Ingelgård, Ingolf Griebsch, David Cella, Andrew Trigg
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 8, Iss 1, Pp 1-11 (2024)
Abstract Background Breast cancer is one of the most common cancers in women. Patient-reported outcome measures are used to evaluate patients’ health-related quality of life in clinical breast cancer studies. This study evaluated the structure, val
Externí odkaz:
https://doaj.org/article/c8c133fb5818480080b343a7b39677fb
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 837-842 (2024)
Background: Due to its indolent biology and high estrogen receptor positivity of mucinous breast cancer, vast majority of locally advanced mucinous breast cancer (LABC) are treated with first-line endocrine therapy. Case Presentation: A 50-year-old w
Externí odkaz:
https://doaj.org/article/6070d88ab98748d6aba39af661c93a57
Autor:
Zhe-Yu Hu, Binliang Liu, Ning Xie, Xiaohong Yang, Liping Liu, Huawu Xiao, Jing Li, Hui Wu, Jianxiang Gao, Jun Lu, Xuming Hu, Min Cao, Zhengrong Shui, Can Tian, Quchang Ouyang
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Aims This investigation aims to elucidate the treatment status of advanced HR+/HER2- breast cancer patients in Hunan Province of Central Southern China from November 2021 to December 2022. Methods Data from 301 patients with advanced HR+/HER
Externí odkaz:
https://doaj.org/article/e9c30214395a45e9b2c6da56ab5e2a2c
Publikováno v:
Современная онкология, Vol 26, Iss 2, Pp 182-189 (2024)
The classification of breast cancer (BC) by immunohistochemical phenotypes is widely used in routine clinical practice. However, the genetic profile of the tumor does not always correspond to the pathomorphological one, which can significantly affect
Externí odkaz:
https://doaj.org/article/9bd059acb1804b48b14f790646bef706
Autor:
Rexeena V. Bhargavan, Nisha Prasannan, K.M. Jagathnath Krishna, Paul Augustine, Kurian Cherian
Publikováno v:
South Asian Journal of Cancer, Vol 13, Iss 03, Pp 170-176 (2024)
Externí odkaz:
https://doaj.org/article/1583a52fe43c4eb88fc75d7a27412945
Autor:
Marcin Kubeczko, Anna Polakiewicz-Gilowska, Andrea D’Amico, Olgierd Chrabański, Katarzyna Świderska, Ewa Chmielik, Sławomir Blamek, Daria Handkiewicz-Junak, Michał Jarząb
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundCyclin-dependent kinase 4/6 (CDK4/6) inhibitors have demonstrated a survival benefit in the second-line treatment of patients with hormone receptor-positive human epidermal growth factor receptor 2-negative advanced breast cancer. However,
Externí odkaz:
https://doaj.org/article/9d9e1f7a93a64468bcf194119069923b
Autor:
Maria Inês Teodoro, Alexandra Mayer, Ana da Costa Miranda, Hugo Nunes, Filipa Alves da Costa, António Lourenço
Publikováno v:
Journal of Pharmaceutical Policy and Practice, Vol 17, Iss 1 (2024)
ABSTRACTBackground: Monotherapy with aromatase inhibitors and fulvestrant were the standard-of-care for hormone receptor-positive (HR+)/human epidermal growth factor receptor-type2 negative (HER2-) advanced breast cancer, before integration of cyclin
Externí odkaz:
https://doaj.org/article/fdc3f7032a734bf581294a7de2104447